Based on a single-arm trial, the FDA has granted an accelerated approval to an immune boosting PD-L1 inhibitor drug for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Bladder cancer is one of the most common urological malignancies. As per the Indian cancer registry data in men, it is the ninth most common cancer accounting for 3.9% of all cancer cases.
Age, gender, and racial factors all affect the survival and prognosis of patients with bladder cancer. In such scenario, the newly approved drug may prove useful to manage bladder cancer. Features Of New Drug: The new drug, durvalumab , belongs to a new class of medicines called PD-L1 inhibitors…
